BCR-Abl-targeting TKIs inhibit the activity of the BCR-Abl fusion protein, which is characteristic of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [63]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.